Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by a unique BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) were developed to target the BCR-ABL oncoprotein, inhibiting its abnormal kinase activity. TKI treatments have significantly improved CML patient outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jialu, Pettit, Nathan, Talburt, John, Wang, Shanzhi, Weissman, Sherman M., Yang, Mary Qu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695508/
https://www.ncbi.nlm.nih.gov/pubmed/36430822
http://dx.doi.org/10.3390/ijms232214335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695508/
https://www.ncbi.nlm.nih.gov/pubmed/36430822
http://dx.doi.org/10.3390/ijms232214335

Ejemplares similares